Best Buy in Public Health or Luxury Expense?
نویسندگان
چکیده
منابع مشابه
Why Do Consumers Buy Counterfeit Luxury Brands?
Vol. XLVI (April 2009), 247–259 247 © 2009, American Marketing Association ISSN: 0022-2437 (print), 1547-7193 (electronic) *Keith Wilcox is a doctoral candidate in Marketing (e-mail: [email protected]), and Sankar Sen is Professor of Marketing (e-mail: [email protected]), Baruch College, City University of New York. Hyeong Min Kim is Assistant Professor of Marketing, Carey B...
متن کاملA physically active lifestyle--public health's best buy?
Leaders A physically active lifestyle public health's best buy? Times have changed. Many people spend most of their working time in the office, sitting behind computer terminals , PCs or laptops. Death is no longer from a mono-causal, infectious disease, but by multi-causal chronic diseases. Lifestyle factors, such as smoking, excessive alcohol intake, nutrition (for example, a too high intake ...
متن کاملBe physically active: the best buy in promoting heart health.
This editorial refers to ‘‘Low physical activity as a predictor for total and cardiovascular disease mortality in middle-aged men and women in Finland’’ by N.C. Barengo et al. on page 2204 and ‘‘Joint effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease among middle-aged Finnish men and women’’ by G. Hu et al. on page ...
متن کاملDoes More Public Health Spending Buy Better Health?
BACKGROUND In this article, we attempt to address a persistent question in the health policy literature: Does more public health spending buy better health? This is a difficult question to answer due to unobserved differences in public health across regions as well as the potential for an endogenous relationship between public health spending and public health outcomes. METHODS We take advant...
متن کاملPharmacogenomic technologies: a necessary "luxury" for better global public health?
BACKGROUND Pharmacogenomic technologies aim to redirect drug development to increase safety and efficacy of individual care. There is much hope that their implementation in the drug development process will help respond to population health needs, particularly in developing countries. However, there is also fear that novel pharmacogenomic drugs will remain too costly, be designed for the needs ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Surgery
سال: 2019
ISSN: 0003-4932,1528-1140
DOI: 10.1097/sla.0000000000003263